Alpha Emitters Market by Type and Application – Industry Analysis, Size, Share, Growth Trends and Forecasts (2016 – 2021)

Report Bazzar has released its latest research-based report entitled ‘Alpha Emitters market.' This comprehensive report provides a holistic approach to the market growth with a detailed and precise analysis of the overall competitive scenario of the Alpha Emitters Market worldwide along with the key trends and latest technologies, playing a prominent role in the Alpha Emitters market growth over the predicted period. It also takes into account the market trends, aspects like drivers, barriers, challenges, and opportunities that impact the market and presents statistical and analytical account on it. This research report features a comprehensive discussion about the current scenario to estimate trends and prospects of the Alpha Emitters market soon. Moreover, it provides dynamic and statistical insights pertaining to the market at both regional as well as global scale.

For Free Sample Copy, click here: http://www.reportbazzar.com/request-sample/?pid=893917&ptitle=Global+Alpha+Emitters+Market+by+Type+and+Application+%26%238211%3B+Industry+Analysis%2C+Size%2C+Share%2C+Growth+Trends+and+Forecasts+%282016+%26%238211%3B+2021%29&req=Sample

The global market for alpha emitters is currently estimated to be valued at $107 million for the year 2015 and is poised to reach $283 million by the end of 2020. The CAGR during this period of forecast is 21.5%.
Alpha emitter radionuclide is considered to be a new approach to tackle cancer and related issues. Alpha emitter provides many advantages when compared to beta emitters and photon therapy, making it an increasingly preferred mode of treatment. As a result, this has caught the attention of major players interested in capitalizing the market potential.
Alpha emitters are currently used in the process of Targeted Alpha Therapy (TAT), where in an alpha emitter radionuclide exposes a certain amount of radiation dose to tumor cells, at a very early stage or in the state of metastasis, and destroys the respective cancer cells. In contrast to chemotherapy, TAT allows easy discrimination between the healthy cells and cancer cells. This is helpful in reducing the side effects associated with Chemotherapy.
The global market for alpha emitters can be segmented on the basis of radionuclide used – Terbium, Astatine, Bismuth, Actinium, Radium, Lead, Bismuth (Bi-213) and Others; type of medical application – Endocrine tumors, Lymphoma, Bone metastasis, Glioma, Melanoma, Pancreatic Cancer, Ovarian Cancer, Thyroid and Others; on the basis of Geography – North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Major drivers contributing to growth of the market are increasing incidences of cardiac & cancer ailments, increased awareness about the potential benefits of targeted alpha therapy and increasing availability of radiopharmaceuticals. However, shorter life of radiopharmaceuticals, need for high capital investment, stringent regulatory framework and reimbursement issues are the major factors impacting market growth.

To view the table of contents and know more details please visit: http://www.reportbazzar.com/product/global-alpha-emitters-market-by-type-and-application-industry-analysis-size-share-growth-trends-and-forecasts-2016-2021/

Table Of Contents – Major Key Points

1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1 REPORT DESCRIPTION
2.2 RESEARCH METHODOLOGY
3. MARKET OVERVIEW
3.1 MARKET SEGMENTATION
3.2 MARKET DRIVERS
3.1.1 INCREASING INCIDENTS OF CANCER AND CARDIAC AILMENTS
3.1.2 INCREASING SPECT AND PET APPLICATIONS
3.1.3 GROWING PUBLIC AWARENESS FOR POTENTIAL BENEFITS OF NEW TREATMENTS LIKE TARGETED ALPHA THERAPY
3.2 MARKET CONSTRAINTS
3.2.1 SHORT HALF LIFE OF RADIOPHARMACEUTICALS
3.2.2 HIGH CAPITAL INVESTMENT
3.2.3 REGULATORY GUIDELINES
3.2.4. REIMBURSEMENT
3.3 OPPORTUNITIES
3.3.1 INCREASING IMAGING TECHNOLOGIES
3.3.2 POTENTIAL RADIOISOTOPES IN PIPELINE
3.3.3 INCREASING NEUROLOGICAL APPLICATIONS
3.3.4 CYCLOTRON BASED PRODUCTION
3.4 THREATS
3.4.1 SHUTDOWN OF NUCLEAR REACTORS
4. GLOBAL ALPHA EMITTERS MARKET SEGMENTATION
4.1 SEGMENTATION BY TYPE OF RADIONUCLIDE
4.1.1 TERBIUM (Tb-161)
4.1.2 ASTATINE (AT-211)
4.1.3 BISMUTH (BI-212)
4.1.4 ACTINIUM (AC-225)
4.1.5 RADIUM (RA-223)
4.1.6 LEAD (PB-212)
4.1.7 BISMUTH (BI-213)
4.1.8 OTHERS
4.2 SEGMENTATION BY APPLICATION
4.2.1 GLIOMA
4.2.2 MELANOMA
4.2.3 PANCREATIC CANCER
4.2.4 OVARIAN CANCER
4.2.5 THYROID
4.2.6 BONE METASTASIS
4.2.7 LYMPHOMA
4.2.8 ENDOCRINE TUMORS
4.3 SEGMENTATION BY GEOGRAPHY
4.3.1 NORTH AMERICA
4.3.1.1 US
4.3.1.2 CANADA
4.3.1.3 MEXICO
4.3.2 EUROPE
4.3.2.1 GERMANY
4.3.2.2 UK
4.3.2.3 FRANCE
4.3.2.4 SPAIN
4.3.2.5 ITALY
4.3.3 ASIA-PACIFIC
4.3.3.1 INDIA
4.3.3.2 CHINA
4.3.3.3 SOUTH KOREA
4.3.3.4 JAPAN
4.3.4 LATIN AMERICA
4.3.4.1 BRAZIL
4.3.4.2 CHILE
4.3.4.3 ARGENTINA
4.3.5 MIDDLE EAST & AFRICA
5. COMPETITIVE LANDSCAPE
5.1 MERGERS, ACQUISITIONS & SPIN OFFS
5.2 COLLABORATIONS
5.3 PRODUCT LAUNCHES
6. COMPANY PROFILES
6.1 IBA GROUP
6.2 LANTHEUS MEDICAL IMAGING
6.3 TRIAD ISOTOPES
6.4 SIEMENS HEALTHCARE (PETNET SOLUTIONS)
6.5 NTP RADIOISOTOPES
6.6 ACTINIUM PHARMACEUTICALS
6.7 BAYER HEALTHCARE

Check Discount: http://www.reportbazzar.com/discount-form/?pid=893917&ptitle=Global+Alpha+Emitters+Market+by+Type+and+Application+%26%238211%3B+Industry+Analysis%2C+Size%2C+Share%2C+Growth+Trends+and+Forecasts+%282016+%26%238211%3B+2021%29&req=Discount

About Us:

Reportbazzar.com is your trusted source for the most inclusive and informative assortment of market research reports designed to empower you with the latest in industry information that translates to time and cost savings for your business. We not only help you give wing to your latent business ideas but also facilitate you in taking the best informed and strategic decisions that guarantee success in your most promising business endeavors.

Contact Us:

ReportBazzar
30 Wall Street, 8th floor,
New York, NY 10005.United States.
US: +1 (212) 389-6363
India: +91 20 66528525
Email Id: sales@reportbazzar.com
Website: http://www.reportbazzar.com/

This release was published on openPR.